Freenome CEO and leadership

Mike brings nearly three decades of experience to his role as Freenome's Chief Executive Officer, building on a proven record of delivering transformative diagnostic technologies that help clinicians drive better outcomes for their patients. Previously, Mike served as the company's Chief Business Officer, where he led Freenome's corporate and business development, product management, clinical development and operations, program management, and marketing teams. He also oversaw partnerships with biopharma companies, academic medical centers, and health systems where our multiomics platform is deployed to move research and medicine forward.

Mike came to Freenome from Foundation Medicine, where he served as SVP of Commercial Operations and led a cross-functional team to expand the appropriate use of next-generation sequencing technologies in cancer.

Other experience in roles at Thermo Fisher, Luminex, Roche Molecular Systems, Roche Diagnostics, and Abbott Diagnostics include general management of global businesses and leadership of multi-national commercial teams to bring innovative technologies to mainstream utilization in clinical care.

Mike holds a B.S. in Biological Sciences and an MBA from the University of Wyoming.

Medically-qualified entrepreneur focused on improving outcomes for patients through applications of machine learning and data science to prevent the diseases of aging.

With the knowledge and skills he gained as a biotechnology entrepreneur, Riley is helping to make Freenome’s vision of a cancer-free world a reality. As the company’s co-founder and Chief Operating Officer, Riley heads the clinical and commercial development of Freenome’s noninvasive tests for early cancer detection and treatment selection.

A Thiel Fellow, Riley developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. While earning his degree in molecular biology at Dartmouth, Riley co-authored several publications and worked as a visiting scientist with Novartis.

In addition to his work as a scientist, Riley worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of a strong organizational culture firsthand. Riley’s previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.

Gabe is the CEO and Co-Founder of Freenome, a cancer screening company. Gabe worked at Apple and the Glyde corporation as a software engineer. He earned an undergraduate degree in chemistry and computational biology from Cornell and did graduate work at the University of Pennsylvania.

As Freenome’s Chief Medical Officer and Clinical Laboratory Director, Girish oversees the development and validation of Freenome’s tests and helps navigate the regulatory and reimbursement complexities of the healthcare industry. He continues to serve as a member of CMS’ Medicare Evidence Development & Coverage Advisory Committee.

Previously, Girish was Director of Laboratory Science for Palmetto’s MolDX program, which oversees coverage and reimbursement for molecular testing for over half of the Medicare population. In prior leadership roles at Life Technologies, Ariosa Diagnostics, and Crescendo Bioscience, he oversaw the development, validation, launch, and commercialization of tests in oncology, fetal-maternal health, and rheumatology. In roles at Panorama Capital and RiverVest Venture Partners, Girish focused on life science investments, serving on the boards of several portfolio companies, including Presidio Pharmaceuticals, PowerVision, and Phenomix.

Girish holds an MD, PhD in molecular neuroscience from Washington University in St. Louis, and subspecialized in molecular genetic pathology at Stanford University, where he served as adjunct faculty. He completed undergraduate work at Rice University, and postgraduate studies at the University of London as a Marshall Scholar.

Medically-qualified entrepreneur focused on improving outcomes for patients through applications of machine learning and data science to prevent the diseases of aging.

With the knowledge and skills he gained as a biotechnology entrepreneur, Riley is helping to make Freenome’s vision of a cancer-free world a reality. As the company’s co-founder and Chief Operating Officer, Riley heads the clinical and commercial development of Freenome’s noninvasive tests for early cancer detection and treatment selection.

A Thiel Fellow, Riley developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. While earning his degree in molecular biology at Dartmouth, Riley co-authored several publications and worked as a visiting scientist with Novartis.

In addition to his work as a scientist, Riley worked as an analyst at Morgan Stanley and an associate at Bridgewater, where he observed the positive impact of a strong organizational culture firsthand. Riley’s previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions.

Gabe is the CEO and Co-Founder of Freenome, a cancer screening company. Gabe worked at Apple and the Glyde corporation as a software engineer. He earned an undergraduate degree in chemistry and computational biology from Cornell and did graduate work at the University of Pennsylvania.

Gabe is the CEO and Co-Founder of Freenome, a cancer screening company. Gabe worked at Apple and the Glyde corporation as a software engineer. He earned an undergraduate degree in chemistry and computational biology from Cornell and did graduate work at the University of Pennsylvania.